Acute cardiac care & resuscitation
Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine
Authors' conclusion
Thus, the combination therapy with LS and BR seems to be a safe and potentially beneficial therapeutic concept for the treatment of PPCM patients with CS.
Study context
- Population
- PPCM mouse model (STAT3 CKO) and PPCM patients with cardiogenic shock from the German PPCM registryregistry patients with cardiogenic shock (CS)
- Participants
- 17 participants
- Comparison
- Levosimendan alone vs levosimendan plus bromocriptine
- Levosimendan (LS) + bromocriptine (BR)n = 17
- Outcome
- Cardiac function and mortality (PPCM mouse model); acute-phase survival and LVEF (registry patients with CS)
Methodological detailsPPCM mouse model (cardiomyocyte-specific STAT3 knockout), German PPCM registry
- PPCM mouse model (cardiomyocyte-specific STAT3 knockout)
- German PPCM registry
Main finding
As reported in the abstract
| Group | Value | LVEF at 3-month follow-up (registry) |
|---|---|---|
| LS + BR | 40 ± 19 % | 40 ± 19% |
LS + BR
Value40 ± 19 %
LVEF at 3-month follow-up (registry)40 ± 19%
Original publication
Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine. Eur J Heart Fail. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →